# Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study

> **NCT05417139** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 43 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **OTHER:** Immunotherapy+induction chemotherapy+radiotherapy

## Key facts

- **NCT ID:** NCT05417139
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2023-07-01
- **Final completion:** 2025-07-01
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2022-06-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05417139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05417139, "Sintilimab Combined With Chemotherapy and Radiotherapy in Newly Diagnosed Metastatic Nasopharyngeal Carcinoma: A Multicenter Study". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT05417139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*